Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 19/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141262 | 0.96 | FGFR4 (0.39) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL23527756 | 0.93 | FGFR4 (0.36) | FGFR4 | |
| SCHEMBL21314546 | 0.89 | FGFR4 (0.38) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL28337160 | 0.88 | FGFR4 (0.38) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL14380644 | 0.83 | MPO (0.38) | FGFR4 | |
| SCHEMBL3140159 | 0.82 | SMN1; SMN2 (0.38) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL5823603 | 0.81 | FGFR4 (0.36) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL28311247 | 0.80 | FGFR4 (0.35) | FGFR4MEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL20158352 | 0.79 | MPO (0.39) | FGFR4 | |
| SCHEMBL20517697 | 0.79 | NOTUM (0.41) | FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | AVPR1A, AVPR1B, ADRB3 | FGFR4 1076/4885MEN1 2504/4885TSHR 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.